GeoVax Labs, Inc.
Business
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary MVA and gene-therapy platforms. Lead candidates include GEO-MVA (Modified Vaccinia Ankara vaccine for mpox and smallpox on expedited European regulatory pathway), Gedeptin® (oncolytic gene-directed enzyme prodrug therapy for solid tumors), and GEO-CM04S1 (multi-antigen COVID-19 vaccine in Phase 2 trials). The company pursues regulatory approval and commercialization through internal development and selective licensing partnerships with academic, governmental, and industry collaborators.
Summary from 10-K filed 2026-04-15
Financials
Consolidated Statement of Income
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Revenue from government contract | 2 | 4 | 0 | 81,526 | 385,501 | |
| Research and development | 18 | 24 | 21 | 9 | 16 | |
| General and administrative | 6 | 5 | 6 | 5 | 4 | |
| Total operating expenses | 24 | 29 | 27 | 14 | 19 | |
| Loss from operations | −22 | −25 | −27 | −14 | −19 | |
| Interest income | 174,276 | 173,359 | 776,177 | 7,439 | 4,736 | |
| Interest expense | 0 | 21,375 | 0 | — | — | |
| Total other income (expense) | 174,276 | 151,984 | 776,177 | 7,439 | 175,506 | |
| Net loss | −21 | −25 | −26 | −14 | −19 | |
| Net loss per common share (in dollars per share) | −22.4 | −120.46 | −14.29 | −12.39 | −3.04 | |
| Weighted average shares outstanding (in shares) | 958,443 | 207,482 | 2 | 1 | 6 |
Consolidated Balance Sheet
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Cash and cash equivalents | 3 | 6 | 6 | 28 | 11 | |
| Government contract receivable | 0 | 659,409 | 0 | — | — | |
| Prepaid expenses and other current assets | 2 | 2 | 1 | 1 | 156,240 | |
| Total current assets | 5 | 8 | 8 | 29 | 12 | |
| Property and equipment, net | 108,830 | 149,974 | 209,689 | 234,912 | 156,938 | |
| Operating lease right-of-use assets | 831,440 | 0 | — | — | — | |
| Other assets | 86,947 | 71,010 | 1 | 2 | 11,010 | |
| Total assets | 6 | 8 | 9 | 31 | 12 | |
| Accounts payable | 790,750 | 2 | 3 | 2 | 2 | |
| Accrued expenses | 882,816 | 1 | 716,931 | 3 | 3 | |
| Operating lease liability, current portion | 263,135 | 0 | — | — | — | |
| Total current liabilities | 2 | 3 | 4 | 5 | 5 | |
| Operating lease liability, net of current portion | 580,035 | 0 | — | — | — | |
| Total liabilities | 3 | 3 | — | 5 | 7 | |
| Commitments and Contingencies | — | — | — | — | — | |
| Common stock, $.001 par value: Authorized shares - 150,000,000 Issued and outstanding shares 1,732,147 and 421,475 at December 31, 2025 and 2024, respectively | 1,732 | 421 | 1,977 | 1,756 | 6,382 | |
| Additional paid-in capital | 155 | 134 | 110 | 105 | 69 | |
| Accumulated deficit | −151 | −129 | −104 | −78 | −64 | |
| Total stockholders equity | 4 | 5 | 6 | 27 | 4 | |
| Total liabilities and stockholders equity | 6 | 8 | 9 | 31 | 12 |
Consolidated Statement of Cash Flows
| Concept | Trend | FY 2025 2025-12-31 | FY 2024 2024-12-31 | FY 2023 2023-12-31 | FY 2022 2022-12-31 | FY 2021 2021-12-31 |
|---|---|---|---|---|---|---|
| Depreciation expense | 68,756 | 95,368 | 74,169 | 56,284 | 38,521 | |
| Stock-based compensation expense | 1 | 528,644 | 1 | 902,074 | 369,987 | |
| Government contract receivable | 659,409 | −659,409 | 0 | 49,006 | 133,657 | |
| Prepaid expenses and other current assets | −414,544 | −352,047 | −114,488 | −1 | −16,270 | |
| Other assets | −27,623 | −1 | 986,498 | −2 | 0 | |
| Accounts payable and accrued expenses | −1 | −412,549 | −1 | −3 | 7 | |
| Total adjustments | −9,198 | 316,785 | 793,123 | −5 | 7 | |
| Net cash used in operating activities | −21 | −25 | −25 | −19 | −11 | |
| Purchase of equipment | −27,612 | −20,653 | −48,946 | −134,258 | −47,718 | |
| Net cash used in investing activities | −27,612 | −20,653 | −48,946 | −134,258 | −47,718 | |
| Net proceeds from issuance of notes payable related parties | 0 | 135,000 | 0 | — | 0 | |
| Repayment of notes payable related parties | 0 | −150,000 | 0 | 0 | −27,864 | |
| Net proceeds from sale of common stock and warrants | 19 | 21 | 0 | 28 | 9 | |
| Net proceeds from warrant exercises | 156,209 | 2 | 4 | 8 | 3 | |
| Net cash provided by financing activities | 19 | 24 | 4 | 35 | 13 | |
| Net increase (decrease) in cash and cash equivalents | −2 | −945,648 | −21 | 16 | 2 |
Filings
Material Events
Insiders
Institutional Holders
Frequently asked questions
What is GeoVax Labs, Inc.'s CIK number?
GeoVax Labs, Inc.'s SEC CIK number is 0000832489 (832489). The CIK (Central Index Key) is the permanent identifier the SEC assigns to every EDGAR filer — unlike a ticker symbol, it never changes.
Where can I find GeoVax Labs, Inc.'s SEC filings?
All of GeoVax Labs, Inc.'s EDGAR filings — 10-K annual reports, 10-Q quarterly reports, 8-K material events, and insider transactions — are listed on this page, sourced live from SEC EDGAR.
When did GeoVax Labs, Inc. last report earnings?
GeoVax Labs, Inc. (GOVX) most recently filed an earnings 8-K with the SEC on May 14, 2026, furnishing its results under Item 2.02 (Results of Operations and Financial Condition). The earnings press release is attached to that filing (accession 0001437749-26-017070). This is GeoVax Labs, Inc.'s most recent earnings filing of record — not a forecast of its next earnings date.
What is GeoVax Labs, Inc.'s most recent earnings 8-K?
GeoVax Labs, Inc.'s latest earnings 8-K (Item 2.02) was filed May 14, 2026 under accession 0001437749-26-017070. It carries the quarterly or annual earnings press release — the earliest official, SEC-filed version of the results.
View GeoVax Labs, Inc.'s latest earnings 8-K →
Look up any company's CIK number →